Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Expert Rev Vaccines. 2021 Jun 9;20(7):827–837. doi: 10.1080/14760584.2021.1935248

Figure 1:

Figure 1:

Direct identification of cancer neoantigens. HLA epitopes are eluted from tumor cells in parallel to whole exome sequencing of the tumor. Variant calling of WES data is performed against reference sequence to generate a patient specific mutational database. Eluted ligands, sequenced by MS, are compared to this database to identify neoantigen candidates.